SWITCH SWEDEHEART Trial Finds Prasugrel Reduces Bleeding Risks

The SWITCH SWEDEHEART trial of 17,095 patients found that prasugrel matches ticagrelor in preventing cardiovascular events but results in significantly lower major bleeding.

At one year, major bleeding occurred in 4.2% of patients on the prasugrel policy compared to 4.4% for those on the ticagrelor policy.

The study, published in the New England Journal of Medicine, utilized a stepped-wedge design across seven Swedish regions to evaluate treatment policies in real-world clinical practice.